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Tissue-engineered blood vessels (TEBV) can serve as vascular grafts and may also play an important 
role in the development of organs-on-a-chip. Most TEBV construction involves scaffolding with 
biomaterials such as collagen gel or electrospun fibrous mesh. Hypothesizing that a scaffold-free 
TEBV may be advantageous, we constructed a tubular structure (1 mm i.d.) from aligned human 
mesenchymal cell sheets (hMSC) as the wall and human endothelial progenitor cell (hEPC) coating 
as the lumen. The burst pressure of the scaffold-free TEBV was above 200 mmHg after three weeks 
of sequential culture in a rotating wall bioreactor and perfusion at 6.8 dynes/cm2. The interwoven 
organization of the cell layers and extensive extracellular matrix (ECM) formation of the hMSC-
based TEBV resembled that of native blood vessels. The TEBV exhibited flow-mediated vasodilation, 
vasoconstriction after exposure to 1 μM phenylephrine and released nitric oxide in a manner similar 
to that of porcine femoral vein. HL-60 cells attached to the TEBV lumen after TNF-α activation to 
suggest a functional endothelium. This study demonstrates the potential of a hEPC endothelialized 
hMSC-based TEBV for drug screening.
Drug screening and toxicity studies are crucial steps in the drug development process1,2. Although any 
drug candidate has to pass extensive in vitro cell-based assays and in vivo animal studies before reach-
ing clinical trials, many still fail to progress to commercialization, with an attrition rate approaching 
80% of drugs entering a Phase I clinical trial3. One drawback of most pre-clinical studies is the failure 
to recapitulate the human physiological conditions. In vitro cell-based assays lack the complex nature 
of the three-dimensional microenvironment to effectively model tissues or organs4,5. The responses of 
non-primate animal studies on the other hand cannot be extrapolated to humans due to cross-species 
discrepancy. In addition, the time and resources required to construct an animal model appropriate 
for a specific pathophysiological behavior through surgery or transgenics further incentivize a different 
approach to advance drug development. An emerging trend is to create an in vitro microphysiological 
system comprising tissue-engineered constructs generated from human cells6–8.
One essential and often neglected tissue component of an in vitro microphysiological system for 
drug screening is the blood vessel9. Current organ-on-a-chip models connect one tissue compart-
ment to another via plastic channels. However, in vivo a drug is exposed to a functional endothelium. 
Drug-induced vascular injury in animals often confounds the toxicological evaluation in the develop-
ment of new drugs because of mismatches with humans10,11. In addition, a functional vasculature is cru-
cial for proper gas and nutrient transport to the surrounding tissues. The failure of vascular function can 
lead to various diseases, to which many drugs under development are targeting12. Thus, the development 
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of a functional artificial blood vessel mimicking the native human vessel is important for drug screening 
as well as for the construction of an integrated microphysiological system.
The vast majority of tissue-engineered blood vessel (TEBV) development has relied on the use of scaf-
folds such as synthetic polymers and hydrogels. Despite extensive research, a TEBV that exhibits satis-
fying functional, biocompatible and mechanical properties has proven difficult to achieve13,14. L’Heureux 
et al. and Niklason et al. showed separately that a TEBV consisting of only cells and extracellular matrices 
without any synthetic or exogenous materials could exhibit the desirable functional characteristics15,16. 
Furthermore, L’Heureux et al. validated the use of cell sheets to produce a functional TEBV with smooth 
muscle cells (SMCs) and endothelial cells (ECs)17. Therefore, a scaffold-free TEBV is attractive; the issue 
is what would be convenient and practical cell sources.
Human mesenchymal stem cells (hMSCs) are an attractive cell source for the medial layer of TEBVs 
based on their unique antithrombogenic properties, immune response modulation abilities, and multipo-
tency for differentiation into vascular phenotypes18. Also, they are more readily available and prolifer-
ative for cell sheet formation compared with SMCs19. While mesenchymal stem cells (MSCs) do not 
normally differentiate into SMC phenotypes, co-culture of MSCs with ECs promotes the MSC differen-
tiation towards a more contractile phenotype, and the exposure to flow leads to further enhancement of 
contractile protein expression in MSC20,21.
In this study, we fabricated a small-diameter (1 mm i.d.) TEBV comprising hMSCs in the wall and 
human cord blood derived endothelial progenitor cells (hEPCs) on the luminal surface without any 
synthetic or exogenous materials. To mimic the 3D spiral and interwoven organization of SMCs in 
native blood vessels, we prepared aligned hMSC cell sheets on nanogratings and wrapped these cell 
sheets around a temporary supporting mandrel in a layer-by-layer fashion. Maturation for 2 weeks and 
removal from the mandrel yielded a tubular structure with circumferentially aligned hMSCs. The lumen 
size of the tubular structure was controlled by the diameter of the mandrel, 1 mm, and the wall thickness 
of the TEBVs was determined by the number of cell layers and maturation time. We characterized our 
scaffold-free TEBV and compared with those obtained from native porcine vessels. Scanning electron 
microscopy (SEM) and immunofluorescent staining were used to visualize micro-/nanoscale features of 
TEBV and detect SMC, EC and extracellular matrix protein expression, respectively. The functionality of 
the TEBV was assessed by vasodilation and vasoconstriction in response to perfusion within the normal 
physiological range. In addition, the functionality of the endothelium was assessed with respect to nitric 
oxide (NO) release and monocyte adhesion. Finally, the mechanical strength was evaluated through burst 
pressure analysis.
Results
Figure 1 shows the overall experimental scheme for fabricating our scaffold-free TEBV. In our scheme, 
four layers of aligned cell sheets, which were grown on nanopatterned PDMS mold (Fig.  2A) under 
hypoxic (2% O2) conditions for 3 weeks, were wrapped around a mandrel (Fig.  2D) and cultured for 
an addition of 2 weeks. We have previously shown that the hypoxic environment helps sustain hMSC 
viability and multipotency and therefore facilitates the formation of a uniform and confluent hMSC 
cell sheet22. The uniform alignment could be seen in microscopic images of hMSCs grown on nanopat-
terned PDMS (Fig.  2B,C). The percentage of cell sheet shrinkage caused by the wrapping process was 
16.7 ± 3.2% for n = 12. Because this measurement was consistent and therefore predictable, the repro-
ducibility of the TEBV fabrication was not affected.
Once the cell sheets had fused and matured into a tubular vessel form, the mandrel, which acts as a 
temporary scaffold, was removed. The outer diameter of the TEBV was measured as 1.13 ± 0.44 mm. The 
Figure 1. Overall experimental scheme of fabricating an hMSC-based scaffold-free TEBV. 
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scaffold-free TEBV was then placed in a perfusion bioreactor, and hEPCs were seeded into the TEBV 
lumen. The perfusion bioreactor was set under a continuous flow at 2 mL/min (physiological shear stress 
of 6.8 dynes/cm2) for a week before any analysis was conducted, as previous studies have shown that 
exposure to flow conditions increase the mechanical strength, contractility and smooth muscle cell dif-
ferentiation of a TEBV23,24. The burst strength of matured TEBVs was measured with a specially designed 
system pressurized with PBS solution. Hydrostatic pressure was increased slowly until sample failure. The 
burst pressure was measured as 342.3 ± 101.2 mmHg. This burst pressure is higher than that of human 
physiological vascular microenvironments (normally < 200 mmHg)25, suggesting that the TEBV can be 
used in microphysiological systems representing native human tissue environments.
Immunofluorescence staining of actin filaments showed that the hMSCs were confluent and uni-
formly aligned in the TEBV after 3 weeks of maturation under perfusion (Fig. 2G,H). In addition, SEM 
images of various TEBV sections (cross-section, longitudinal section showing the lumen, and longitudi-
nal section showing the outer wall) demonstrated that the cell sheets were well fused to create multiple 
layers of the vessel wall with confluent cell density throughout the vessel from the lumen to the exterior 
(Fig. 2I–L). The H&E staining of the TEBV cross section further confirms the maturity of the vessel wall 
(Supplementary Fig. S1).
The functionality of the cell sheet layer of our scaffold-free TEBV was assessed by measuring the 
vasodilation and vasoconstriction of the vessel in response to flow and to 1 μ M phenylephrine, a vaso-
constrictor drug, respectively (Fig.  3). To test vasodilation, the flow rate was gradually increased from 
0.5 to 4 mL/min in double increments. The vessel diameter increased as the flow rate increased. This 
increase was distinct enough to be visualized, as evident in the supplementary video S1 online. The per-
cent increase of the vessel diameter at each phase of flow rate increase is shown in Fig. 3. In addition, the 
amount of nitric oxide (NO) released by the TEBV at each flow rate was measured as another benchmark 
to determine the functionality of the endothelium26. The NO measurements showed a similar trend as 
that of vasodilation: the NO concentration increased with the flow rate. This result agrees with previous 
findings that a functional endothelium produces more NO when exposed to fluid shear stress27.
To test vasoconstriction, phenylephrine, a vasoconstrictor drug that acts as α -adrenergic receptor 
agonist for vascular smooth muscle cells, was added to the perfusion bioreactor. Results indicated that 
1 μ M of phenylephrine treatment reduced the vessel diameter by 4.8 ± 0.3% (Fig.  3). This reduction 
in diameter was not statistically different than the reduction in diameter observed in native porcine 
femoral vein under identical treatment (6.1 ± 1.3%). Furthermore, the amount of NO released by the 
Figure 2. Images of aligned cell sheets and resulting TEBV. (A) SEM image of nanopatterned PDMS; 
(B,C) Phase images of aligned hMSCs grown on nanopatterned PDMS, (D) hMSC sheets wrapped around 
1.3 mm diameter glass rod; (E,F) SEM images of circumferentially aligned hMSC in outer layer of TEBV; 
(G,H) Confocal images showing phalloidin staining (Red) and DAPI (Blue) of TEBV; (I–L) SEM images 
of various TEBV sections demonstrating that the cell sheets were well fused to create multiple layers of the 
vessel wall with confluent cell density throughout the vessel from the lumen to the exterior ((I): TEBV; (J): 
longitudinal section showing lumen; (K): longitudinal section showing the outer wall; and (L): cross-section)
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TEBV under phenylephrine treatment was comparable to that released by native porcine femoral vein 
(p > 0.05).
The level of extracellular matrix production, the extent of hMSC differentiation towards the SMC 
phenotype, and the degree of endothelial coverage of TEBV after 7 days of perfusion was analyzed and 
compared to those of the native vessel (positive control) (Fig. 4A). Immunofluorescent staining against 
ECM components in the basal lamina (collagen IV and laminin), SMC (α -smooth muscle actin), and 
EC (platelet endothelial cell adhesion molecule (PECAM)) markers were performed. The level of each 
marker expression in the TEBV increased after perfusion (from d0 to d7) (data not shown), and became 
comparable to that of the native vessel. The increased expression of collagen IV and laminin in Fig.  4 
showed that hMSCs in the TEBV wall secrete basal lamina ECM proteins that surround the smooth 
muscle layer. Furthermore, the high fluorescence intensity shown for SMC and EC markers indicated 
an MSC-to-SMC differentiation and the presence of a confluent endothelium, respectively. Moreover, 
the immunofluorescent staining in Fig. 4B showed that hMSCs in the TEBV wall aligned perpendicular 
to the direction of flow in the bioreactor. On the other hand, the immunofluorescent staining against 
PECAM showed that endothelial cells aligned parallel to the direction of flow. This observation is consist-
ent with both the staining obtained from the native vessel in Fig. 4A, and previous reports that smooth 
muscle cells tend to orient in a direction perpendicular to the blood flow28, while endothelial cells orient 
in a direction parallel to the blood flow29.
To further test the functionality of the endothelium in the TEBV, monocyte adhesion in the TEBV 
was measured after TNF-α activation. Figure 4C shows the strong attachment of monocyte-like HL-60 
cells on the activated endothelium of the TEBV even after 4 hours of continuous perfusion. The image 
was taken with the lumen facing up, which indicated that the stained HL-60 attached to the endothelial 
cells and beside the aligned smooth muscle cells in the TEBV. The attached cell density at different views 
was measured and shown in Fig. 4D. A relatively good uniformity of endothelium in the TEBV could 
also be seen. In contrast, monocyte adhesion was not observed in the control TEBV without TNF-α 
treatment (data not shown).
Discussion
Microphysiological systems using human cell-based tissues for in vitro drug screening and toxicology 
evaluation may overcome some of the drawbacks associated with rodent animal models due to their 
potential of eliciting a more human-like response. A TEBV mimicking a native vessel would be an 
important addition to an integrated multi-organ microphysiological system, which not only serves as 
a mass transport system for nutrients and cytokines, but also more faithfully recapitulates the in vivo 
situation where drug exposure to the endothelium may obscure the toxic effects in other tissues. Such 
TEBV can also act as a screening system for drugs to treat vascular diseases such as atherosclerosis. 
In this study we created a scaffold-free TEBV mimicking native vessel made up of aligned hMSC cell 
sheets and hEPCs. By removing any exogenous and synthetic materials from the TEBV construction, we 
hypothesize that such TEBV may have a greater likelihood of achieving acceptable functionality for drug 
screening30,31. Work is underway to compare the functionality of this scaffold-free configuration with the 
one involving dense collagen gel in the construction of TEBV. A scaffold-free configuration holds the 
advantage of achieving a high cell density in a scaffold-based TEBV32. After all, a native blood vessel 
Figure 3. Response of scaffold-free TEBVs to flow rate (A) and 1 μM phenylephrine (B). The flow rate was 
gradually increased from 0.5 to 4 mL/min in doubling increments and the vessel diameter increased as the 
flow rate increased (*p < 0.05). The decrease of vessel diameter and the amount of NO release in response to 
the drug was comparable to those of native vessels (**p > 0.05).
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contains a highly dense SMC layer. Pre-aligning the cells in the cell sheet method may also approximate 
the 3D spiral and interwoven organization that exists in the medial layer of a native blood vessel.
The cell sheet-based construction loses the ancillary mechanical support of a scaffold, which may be 
detrimental for in vivo applications. This concern is alleviated for drug testing in vitro. Nevertheless, the 
burst pressure obtained for the 3-layered TEBV in this study is within range of that for native human 
vessel25. Moreover, the mechanical properties of the proposed TEBV can be improved by using more cell 
layers as well as a longer maturation time. However, such gain must be weighed against the materials and 
time needed to construct the TEBV. On balance, the protocol described in this study appears adequate 
to produce a construct reasonably functional within five weeks.
The functions of the TEBV were assessed in terms of flow-mediated vasodilation, phenylephrine-induced 
vasoconstriction, and the corresponding NO release under each stimulus. Flow-mediated vasodilation 
is a noninvasive diagnosis for detecting endothelial dysfunction in systemic arteries, particularly for 
patients with risk of atherosclerosis or coronary artery disease33,34. Studies indicate that an increase in 
flow rate causes dilation of vessels by releasing endothelium-derived relaxing factor such as NO35, and 
this dilation is dependent on an intact, functional endothelium26. In accordance with the previous find-
ings, our results shown in Fig. 3 indicate that increase in flow rate causes an increase in both the vessel 
Figure 4. Confocal images showing immunostaining for PECAM, SMA, Type IV collagen, and laminin 
of TEBV cultured for 7 days in the perfusion chamber and native porcine femoral vein, respectively (A). 
Immunofluorescence staining images show that the hMSCs align perpendicular to the direction of flow in 
the bioreactor, which is consistent with previous report that smooth muscle cells tend to orient in a direction 
perpendicular to blood flow (B). Monocyte adhesion assay shows the attachment of HL-60 s (arrows) to the 
endothelial cells and beside the aligned smooth muscle cells in the TEBV (C). Density of the attached HL-60 
cells on the activated endothelium of TEBV is shown in (D). No attached HL-60 cells were observed if the 
TEBV was not endothelialized. Error bar indicates standard error.
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diameter and the NO release. This implies that our TEBV has a functional endothelium that modulates 
vessel tone in response to external stimuli such as flow rate. Indeed, the immunofluorescence staining 
for PECAM in TEBV indicates the presence of a confluent layer of endothelial cells in the vessel lumen 
(Fig.  4). In addition, administration of 1 μ M of phenylephrine, which acts on vascular smooth muscle 
cells to create vasoconstriction36, showed similar percentage decrease in the vessel diameter between the 
TEBV and the native porcine femoral vein (Fig. 3). The level of NO release under phenylephrine treat-
ment was also similar. Therefore, it suggests that the TEBV possesses hMSCs that exhibit a contractile 
SMC phenotype. This was confirmed by the expression of a SMC marker, alpha-smooth muscle actin, 
in Fig. 4. Furthermore, Lee et al. have studied the flow-stimulated perpendicular alignment of SMCs in 
the vessel wall28. They stated that the perpendicular orientation of SMCs is important for the mechanical 
strength and the function of the blood vessels, and such alignment is regulated by mechanotransduction 
mechanisms often observed when SMCs are subjected to high strain28. Thus, the perpendicular orienta-
tion of our hMSCs in the TEBV (Fig. 4B) suggests that the hMSCs exhibit a SMC phenotype and allow 
for proper vascular function.
The monocyte adhesion assay further validated the presence of a functional endothelium in our 
TEBV. Inflammation is a crucial nonspecific defense against tissue damage, irritant or pathogen, and 
the interaction between vascular endothelium and leukocytes is necessary for a complete inflamma-
tory response to develop37. Following injury or a pro-inflammatory stimulus, various cytokines, such as 
TNF-α, induce the up-regulation of adhesion molecule expression on the surface of endothelial cells to 
initiate the binding of leukocytes and develop inflammatory responses38. In this study, we observed the 
adhesion of monocyte-like HL-60 to the endothelial cells in the TNF-α -activated TEBV lumen, but not 
to the TEBV without endothelialization. This demonstrates that a functional endothelium is necessary 
for monocyte adhesion, and that our TEBV contains such mature endothelial layer.
So far our TEBV has only been compared to the native animal vessel. Although the assessments 
demonstrate comparable functionality, there is a need for direct comparison with native human vessels 
under the same stimuli. In fact, the goal of our future studies is to test drug compounds that have shown 
poor correlation between pre-clinical studies and clinical trials, so as to validate the use of TEBV as a 
drug screening platform. In summary, this study is a first step towards the development of a human 
cell-based microphysiological system that incorporates drug exposure to an endothelium as an integral 
part of drug screening.
Methods
Fabrication and characterization of PDMS nanogratings substrates and aligned MSC 
sheets. PDMS substrates with nanogratings of 350 nm line width, 700 nm pitch, and 250 nm depth 
were used for generating pre-aligned MSC sheets. Briefly, the nanopattern was fabricated on the poly(me-
thyl methacrylate)-coated Si wafer by using electron beam lithography and then replicated on PDMS 
(Ellsworth Adhesives, Germantown, WI) using soft lithography. To create multiple copies of PDMS sub-
strates, the original PDMS substrate was imprinted onto polystyrene (PS) disks under molding condi-
tions of 210 °C and 50 kPa for 5 min, followed by cooling to room temperature. A mixture of PDMS resin 
and curing agent (SYLGARD 184 kit, Dow Corning, MI, USA) was poured onto the nanograted PS mold 
(L = 6 cm, W = 4.5 cm) and cured for 2 h at 65 °C. Before culturing MSC on the PDMS substrates, the 
substrates were oxygen-plasma treated with a Trion Phantom II Reactive Ion Etcher for 60 s, 300 mTorr 
chamber pressure, 20 cm3 O2 flow rate, and 20 W RF power. Plasma-treated substrates were immedi-
ately immersed in sterile EtOH for sterilization, and then coated with rat tail collagen I (Sigma-Aldrich, 
Germany) at 15 mg/cm2 for 1 h to facilitate hMSC attachment22,39,40.
Bone marrow–derived hMSCs were generously provided by Darwin J. Prockop of Texas A&M 
Institute for Regenerative Medicine. hMSCs below passage 5 were seeded at 5,000 cells/cm2 on collage 
coated, nanopatterned PDMS substrates and cultured using complete media [α -minimum essential 
medium (Gibco) with 20% fetal bovine serum (Atlanta Biologicals), 1% penicillin/streptomycin (Life 
Technologies, Rockville, MD), and 82.5 μ g/ml L-Ascorbic acid (Sigma-Aldrich)] at 37 °C in a hypoxic 
chamber of 2% O2 for 3 weeks.
The pattern transfer fidelity from mold to replica and cell alignment onto the PDMS substrates were 
examined using scanning electron microscopy (SEM) (FEI XL30 SEM-FEG). Samples, either only the 
PDMS substrate or the PDMS substrate with hMSCs seeded, were fixed, dehydrated and dried, and 
then coated with a 10 nm layer of gold film (Denton Desk IV vacuum sputter coater) to improve sample 
conductivity for SEM imaging.
Fabrication of functional scaffold-free TEBVs. To create a tubular vessel structure using hMSC 
sheets, confluent hMSC layers were carefully detached from the PDMS with tweezers and wrapped onto 
a temporary supporting mandrel (glass rod, 1 mm diameter). Typically four hMSC sheets were rolled 
around a mandrel to form a TEBV. These TEBVs were then stabilized in a complete media inside hypoxic 
chamber overnight to allow the cells to fuse together. For further maturation of the cellular assemblies, 
the cell sheets with the mandrel were cultured in a rotating wall bioreactor (Synthecon, TX) at 37 °C in 
the hypoxic incubator of 2% O2 for 2 weeks. Media was replaced every 5–7 days. The temporary mandrel 
was then removed from the TEBV with tweezers, and the TEBV was inserted into a perfusion chamber 
(KISTECH, Korea).
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Human umbilical cord blood derived endothelial progenitor cells (hEPCs) were isolated as previously 
described41. Umbilical cord blood was obtained from the Carolina Cord Blood Bank. All patient identifi-
ers were removed prior to receipt. The protocol for the collection and the usage of human blood in this 
study was approved by the Duke University Institutional Review Board.
hEPCs (5 × 105 cells/vessel of 1 mm i.d. and 3 cm length) were seeded into the vessel by injection into 
the chamber using a 3 mL syringe with Luer-LokTM Tip (BD Biosciences), and the chamber was rotated 
for 30 min with 0.17 rpm in the incubator to allow for an even attachment of endothelial progenitor cells 
around the vessel lumen. The TEBV was then connected to a perfusion chamber running at a steady flow 
of 2 mL/min and further cultured for 2 weeks in 37 °C and 5% CO221. The overall experimental scheme 
is shown in Fig. 1.
Characterization of scaffold-free TEBV. To examine the mechanical property of TEBV, burst pres-
sure strength was measured. TEBVs were mounted in a system custom-designed for pressurizing individ-
ual vessels until failure. TEBVs were pressurized with water at increments of 300 mmHg in approximately 
2 minutes until rupture.
The biological activity of TEBVs was evaluated after 14 days of culture in perfusion chambers. To 
examine the change in the diameter of the TEBV in response to flow-mediated vasodilation and a vaso-
constrictor drug, phenylephrine, the perfusion chamber connected with TEBVs was placed on a micro-
scope stage (SM3-TZ, Amscope, CA) equipped with a video camera and computer with ImageJ software. 
The chamber was perfused with a culture media at the start of the recording. Vessel diameters were meas-
ured at various flow rates, and before and after perfusion with the vasoconstrictor phenylephrine (1 μ M). 
Measurements were typically taken 5 min after perturbation. Media samples were collected to measure 
nitric oxide (NO) release. Media samples were frozen at − 80 °C and lyophilized (Appropriate Technical 
Resources, Laurel, MD) for 24 h. The lyophilized medium was resuspended into 1/10 of its original vol-
ume in double-distilled water (ddH2O), and mixed with equal volumes of 1X Greiss Reagent (Sigma) in 
a 96 well plate (BMG Labtech, Ortenberg, Germany). After 15 min, spectrophotometric absorbance was 
measured at 540 nm. A standard curve was prepared using sodium nitrite solutions (Sigma) ranging from 
0 to 80 μ M in ddH2O. The values were analyzed by one-way analysis of variance (ANOVA), followed by 
nonparametric LSD tests. A p < 0.05 was considered to indicate statistical significance.
To observe the distribution of vascular extracellular matrix and cellular alignment of matured vessels, 
immunofluorescence staining was performed. TEBVs were fixed with 4% parafomaldehyde (Electron 
Microscopy Sciences) in PBS for 24 h at room temperature, and permeabilized in a blocking solution 
consisting of 0.03 g/ml bovine serum albumin (BSA, Sigma) and 0.1% goat serum (Sigma) dissolved in 
0.2% Triton X-100 (Sigma) diluted with PBS for 2 h. Then, TEBVs were stained with platelet endothe-
lial cell adhesion molecule (PECAM, Abcam, Cambridge, MA), alpha-smooth muscle actin (α -SMA, 
Abcam, Cambridge, MA), Type IV collagen (Abcam, Cambridge, MA) and laminin (Abcam, Cambridge, 
MA) antibodies. Different Alexa Fluor secondary antibodies (Abcam, Cambridge, MA) were used to 
obtain fluorescent colors. Also, the cell nuclei were stained with 4, 6-diamidino-2-phenylindole (DAPI, 
Molecular Probes). After the staining, the samples were then mounted in Fluoro-Gel (Electron Microscopy 
Sciences, Hatfield, PA) and viewed with a Zeiss LSM 510 inverted confocal microscope.
To test the functionality of the endothelium in TEBV, monocytes adhesion onto the activated endothe-
lium was measured. First, HL-60 monocyte-like cells (CCL-240; American Type Culture Collection, 
Rockville, MD) were labeled with 2 μ M CMFDA (Molecular Probes) in culture medium for 30 minutes. 
The TEBV was labeled with 0.5 μ M DAPI (Molecular Probes) after fixation and permeabilization. For 
endothelial activation measurement, the TEBV was perfused with culture medium containing 500 U 
TNF-alpha for 4 hours, and then monocyte-like HL-60 cells (105 cells/mL) were perfused through the 
TEBV at a shear stress of 1.4 dynes (perfusion speed at 2 mL/min) for an additional 40 min. The TEBV 
was gently washed with medium without HL-60 cells three times and then fixed with 4% PFA in PBS. 
The TEBV was then cut open and imaged on the lumen side using a Zeiss LSM 510 inverted confocal 
microscope. For HL-60 cell counting, the fluorescent images showing labeled HL-60 cells were analyzed 
using Image J software.
Ethics Statement
All methods used in this study were carried out in accordance with the approved ethical guidelines of 
all institutions. The study protocol was approved by the Duke University Institutional Review Board.
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